echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Mass spectrometry system and Cong Yao's research group cooperate to reveal the structure and activation mechanism of mammalian PA28αβ-iCP immune proteasome

    Mass spectrometry system and Cong Yao's research group cooperate to reveal the structure and activation mechanism of mammalian PA28αβ-iCP immune proteasome

    • Last Update: 2022-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    (A) Immune proteasome PA28αβ-iCP and cryo-EM structure of iCP, PA28αβ can be bound to one end of iCP or both ends at the same time; (B) The relative spatial arrangement of PA28αβ and iCP; (C) PA28αβ-iCP The interaction interface between PA28αβ and iCP in the complex, where the C-terminal tail of PA28αβ inserted into the iCP loop is represented by the cyan density; (D) A schematic diagram of the molecular mechanism of PA28αβ binding and activating iCP


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.